Key facts
- It has raised $15.3M; the latest was Later Stage VC ($7.6M) in Dec 2025.
- Notable investors include Tech Incubator Program for Startup, Enlight Ventures, Partners Investment, AFW Partners, Medici Investment — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for AulBio
- ·The full record, as it builds
Funding rounds
No funding rounds for AulBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AulBio
Developer of drug delivery technology designed to improve the quality of life of diabetics and obese patients. The company's technology specializes in developing customized technology that has peptide and protein drugs and sustains the drug for a desired period, enabling diabetes and obese patients to reduce the number of injection administrations.
- Sector
- Healthcare
- HQ
- Seongnam, South Korea
- Founded
- 2018
- Employees
- 17
- Website
- aulbio.com/
- Ownership
- Privately Held (backing)
AulBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AulBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AulBio in its N-PORT filings yet. We sweep new filings monthly.